drugset / Trial / NCT07444541
ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
The goal of this clinical trial is to assess the safety and efficacy of ANO31905 in combination with chemotherapy as the first-line treatment for subjects with CLDN18.2-positive locally advanced unresectable or metastatic pancreatic cancer.
Timeline
- Start
- 2026-05
- Primary completion
- 2027-08
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANO31905 | Unknown | 500 ug/kg | — |
| Subject | ANO31905 | Unknown | 800 ug/kg | — |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Background | nanoparticle albumin-bound paclitaxel | Unknown | 125 mg/m2 | Intravenous |